SMTL ID : 5y9t.1

Crystal Structure of EGFR T790M mutant in complex with naquotinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.25 Å

Oligo State

monomer

Ligands

1 x 8RC: 6-ethyl-3-[[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxy-pyrazin e-2-carboxamide(Covalent)

8RC.1: 14 residues within 4Å: Chain A: L.29, V.37, A.54, K.56, M.101, Q.102, L.103, M.104, P.105, G.107, C.108, D.111, R.152, L.155 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:L.29, A:L.29, A:V.37, A:K.56 Hydrogen bonds: A:Q.102, A:M.104, A:M.104

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Hirano, T. et al., Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, inEGFR-Mutated Non-Small Cell Lung Cancer. Mol. Cancer Ther. (2018)

Release Date

2018-07-11

Peptides

Epidermal growth factor receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Epidermal growth factor receptor